T2* MRI and blood tests to predict progression of malignant gliomas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This protocol combines T2* magnetic resonance imaging (an iron-sensitive MRI technique) with blood tests for iron-related cell-death biomarkers in adults newly diagnosed with WHO grade IV malignant glioma. Participants receive serial T2* MRI scans alongside their standard chemoradiation care on the MR Linac, and provide periodic blood samples for biomarker analysis. Imaging and blood biomarker changes are tracked over time to distinguish tumor recurrence from treatment-related changes such as inflammation. The study aims to determine whether these combined measures signal progression earlier or more reliably than standard MRI alone.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \> 21 years
* New pathologically confirmed diagnosis of WHO grade IV malignant glioma
* KPS \> 60
* Ability to give informed consent for standard of care chemotherapy and radiation therapy on the MR Linac and to study procedures for the protocol

Exclusion Criteria:

* History of previous malignancy other than non-melanoma skin cancer in the previous 5 years
* History of iron metabolic disorder such as hemochromatosis
* Inability to undergo MR studies due to size, claustrophobia, or metal implants or devices

Where it's running

• University of Iowa Health Care
  Iowa City, Iowa, United States Recruiting

Study contacts

• Principal investigator: John Buatti, MD — University of Iowa
• Study coordinator: John Buatti, MD
• Email: john-buatti@uiowa.edu
• Phone: (319) 356-7590

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dual-target CAR-NK therapy for adults with recurrent or progressive glioblastoma and other high-grade gliomas

  This study will try giving dual-target CAR-NK cells into the surgical cavity to see if they can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07551336

• Dual-target CAR-NK cell therapy for recurrent glioblastoma and high-grade glioma

  This phase 1 study will test whether injecting dual-target CAR-NK cells into the brain is safe and can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07480941

• Retifanlimab With or Without DFMO for Progressive High-Grade Gliomas

  This trial tests whether retifanlimab, with or without DFMO, is safe and may help treat progressive high-grade gliomas in adults.

  Recruiting Phase 1/2 Mayo Clinic · Rochester, Minnesota · NCT07468136

• Mapping electrical properties in the brain

  This study is testing new MRI methods to see if they can help doctors better understand and diagnose brain tumors by looking at the brain's electrical activity.

  Recruiting Mayo Clinic · Scottsdale, Arizona · NCT06470711

• Investigating the effects of DFMO and AMXT 1501 on brain tumor metabolism

  This study is testing how two drugs, DFMO and AMXT 1501, can change the metabolism of brain tumors in patients after surgery.

  Recruiting Early Phase 1 Mayo Clinic · Rochester, Minnesota · NCT05717153

• Using CARv3-TEAM-E T Cells to treat glioblastoma

  This study is testing the best dose of a new type of immune cell treatment for people with glioblastoma, a serious brain cancer, to see how safe and effective it is.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT05660369

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.